Loading organizations...
10x Genomics is a Pleasanton, California-based life sciences technology company that develops instruments, consumables, and software for single-cell and spatial biology analysis. The publicly traded firm operates a recurring revenue business model, selling proprietary laboratory platforms alongside consumable reagents to academic institutions and pharmaceutical companies. Operating with a global workforce of over 1,200 employees, the enterprise generated 618 million dollars in annual revenue for 2023. Backed by early investors such as Venrock and Paladin Capital Group, the organization completed a 390 million dollar initial public offering on the Nasdaq in 2019 at a valuation of over 3 billion dollars. Its analytical tools have been utilized in cancer research and immunology, resulting in citations across more than 10,000 scientific publications worldwide. 10x Genomics was founded in 2012 by Serge Saxonov, Ben Hindson, and Kevin Ness.
10X Genomics has raised $341.0M across 5 funding rounds.
10X Genomics has raised $341.0M in total across 5 funding rounds.
10x Genomics is a life science technology company that develops innovative instruments, reagents, and software for single-cell, spatial, and in situ analysis to accelerate mastery of biology and advance human health.[1][2][3] It serves academic researchers, pharmaceutical companies, and biotech firms by providing high-resolution tools that enable breakthroughs in oncology, immunology, neuroscience, and drug development, with products cited in over 10,000 publications and adopted by 97 of the top 100 global research institutions.[1][3][5] The company has placed over 4,600 instruments worldwide, holds 1,750+ patents, and continues strong growth through launches like GEM-X Flex for high-scale single-cell profiling and Xenium Protein for spatial multiomics.[1][3][6]
Founded in 2012, 10x Genomics emerged from founders' efforts to overcome limitations in existing genomics tools, focusing on high-throughput single-cell and spatial analysis for complex biological insights.[6] The company quickly gained traction with the 2015 launch of its Chromium System, revolutionizing single-cell library preparation at low cost and high scale.[6] Pivotal expansions included spatial biology platforms like Visium for tissue gene mapping and Xenium for in situ analysis, earning Top 10 Innovations awards from The Scientist in 2015, 2017-2021.[1][6] By 2024-2025, it introduced GEM-X, Visium HD, Xenium Prime, and a roadmap for plate-based workflows and multiomics, targeting 50% sales from biopharma by mid-2025.[6]
10x Genomics rides the spatial biology and multiomics wave, where understanding gene expression in tissue context is transforming drug discovery amid rising failures (90% of candidates flop).[3][6] Timing aligns with AI-driven biology, providing high-quality single-cell data for virtual cell models and therapies like melanoma cell treatments.[3] Market forces favor it: booming biopharma demand (aiming for 50% revenue), genomics market growth, and need for scalable tools beyond traditional methods.[5][6] It influences the ecosystem by empowering 97% of top institutions and pharma, accelerating discoveries in cancer, autoimmune diseases, and beyond, while expanding from research to clinical applications.[1][2][7]
10x Genomics is poised for expansion with its 2025 roadmap, including Chromium mega-scale enhancements, Visium upgrades, and Xenium protein analysis for fuller multiomics.[6] Trends like AI-biology integration, biopharma shift, and spatial tech maturation will propel growth, potentially evolving from research tools to direct clinical impact.[3][6][7] As it masters biology's complexity, 10x continues fueling exponential progress in human health through reliable, breakthrough-enabling innovations.[1][2]
10X Genomics has raised $341.0M across 5 funding rounds. Most recently, it raised $35.0M Series D in January 2019.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 1, 2019 | $35M Series D | Meritech Capital Partners | Andreessen Horowitz, Bessemer Venture Partners, Norwest Venture Partners, Shasta Ventures, Evan Williams, Fidelity Management & Research Company, Wells Fargo | Announced |
| Apr 26, 2018 | $125M Debt Financing | Craig Sherman | Fidelity Management & Research Company, Paladin Capital Group, Silicon Valley Bank, Softbank, Wells Fargo Strategic Capital | Announced |
| Apr 1, 2018 | $50M Series D | — | Andreessen Horowitz, Bessemer Venture Partners, Meritech Capital Partners, Norwest Venture Partners, Shasta Ventures, Evan Williams | Announced |
| Feb 1, 2016 | $75M Series C | Fidelity Management & Research Company | Greylock, Harrison Metal, Venrock, Brad Garlinghouse, Foresite Capital, JS Capital Management, Paladin Capital Group, Softbank | Announced |
| Dec 1, 2014 | $56M Series B | Foresite Capital | Greylock, Harrison Metal, Venrock, Brad Garlinghouse, Morgan Stanley, Paladin Capital Group | Announced |
10X Genomics has raised $341.0M in total across 5 funding rounds.
10X Genomics's investors include Meritech Capital Partners, Andreessen Horowitz, Bessemer Venture Partners, Norwest Venture Partners, Shasta Ventures, Evan Williams, Fidelity Management & Research Company, Wells Fargo, Craig Sherman, Paladin Capital Group, Silicon Valley Bank, SoftBank.
